Indicated in adults for:

- Moderate to severe hypertension as an adjunct to other antihypertensive agents.

- Moderate to severe chronic congestive heart failure as supplementary medication for use in combination along with long-acting nitrates in patients whose optimal doses of diuretics and cardiac glycosides have proved insufficient and ACE inhibitors are unsuitable.

Posology

The dosage should be adjusted to the individual requirements of the patient. Treatment should commence with low doses which, depending on the patient's response, should be increased stepwise to achieve optimal therapeutic effect, whilst minimising unwanted effects.

Due to the complementary mechanism of action, the combination of hydralazine with beta-blockers and diuretics may enable antihypertensive efficacy at lower dose levels and counteract accompanying hydralazine effects such as reflex tachycardia and oedema.

Adults

Hypertension: the initial dose is 25 mg twice daily. This may be increased gradually to a maximum dose of 200 mg daily. The patient's acetylator status must be checked prior to increasing the daily dose beyond 100 mg. The maximum dose in women should not exceed 100 mg (see section 4.4).

Chronic congestive heart failure: Doses vary greatly between individual patients and are generally higher than those used to treat hypertension. Treatment should be initiated in hospital where the patient's individual haemodynamic values can be determined with the help of invasive monitoring. Treatment should continue in hospital until the patient has been established on the required maintenance dose. After progressive titration (initially 25 mg three or four times daily, increasing every second day) maintenance dosage averages 50-75 mg four times daily.

Paediatric population

Hydralazine is not recommended.

Elderly

There is no special dosage requirement. Systemic clearance and blood concentration of hydralazine are not affected by advanced age, though renal elimination may be affected due to diminished kidney function with age. The elderly may also be more sensitive to the hypotensive effects of hydralazine.

Renal impairment and hepatic impairment

In patients with moderate to severe renal impairment (creatinine clearance < 30 mL/min or serum creatinine concentration > 2.5 mg/100 mL or 221 µ mol/L) or hepatic dysfunction, the dosage or the dosing interval must be adapted according to the clinical response to avoid accumulation of the “ apparent” active substance (see section 4.4).

Method of administration

For oral administration only. Swallow the tablets with a glass of water.

Hydralazine is contraindicated in patients with:

- Hypersensitivity to the active substance, dihydralazine or to any of the excipients listed in section 6.1

- Idiopathic systemic lupus erythematosus (SLE) and related diseases

- Severe tachycardia

- High output cardiac failure (e.g. in thyrotoxicosis)

- Myocardial insufficiency due to mechanical obstruction (e.g. in the presence of mitral or aortic stenosis or constrictive pericarditis)

- Cor pulmonale

- Dissecting aortic aneurysm

- Porphyria

Warnings

The “ Hyperdynamic” state of the circulation induced by hydralazine may accentuate certain clinical conditions. Myocardial stimulation may provoke or aggravate angina pectoris. Patients with suspected or confirmed coronary artery disease should be given Hydralazine only under cover of a beta-blocker or in combination with other suitable sympatholytic agents. Beta-blocker medication should be started a few days prior to commencing treatment with Hydralazine.

Patients who have survived a myocardial infarction should not receive Hydralazine until a post-infarction stabilisation phase has been achieved.

Prolonged treatment with Hydralazine (i.e. usually for more than 6 months) may provoke a systemic lupus erythematosus (SLE) like syndrome, especially with doses exceeding 100 mg daily. Initial symptoms are likely to be similar to rheumatoid arthritis (arthralgia, sometimes associated with rash, anaemia, leucopenia, thrombocytopenia and fever) and are reversible upon withdrawal of the drug. In its more severe form, it resembles acute SLE (similar manifestations as the milder form plus pleurisy, pleural effusions and pericarditis), and in rare cases renal and ocular involvement have been reported. Early detection and a timely diagnosis with appropriate therapy (i.e. treatment discontinuation and possibly long-term treatment with corticosteroids may be required to reverse these changes) are of utmost importance in this life-threatening illness to prevent more severe complications, which may sometimes be fatal.

Since such reactions tend to occur more frequently with higher doses and longer duration of treatment and since they are also more common in slow acetylators, the lowest effective dose should be used for maintenance therapy. If 100 mg daily fails to elicit an adequate response, the patient's acetylator status should be evaluated. Slow acetylators and women are at greater risk of developing the SLE-like syndrome and every effort should therefore be made to keep the dosage below 100 mg daily. The patient should be watched for signs and symptoms of the syndrome and if such symptoms develop, the drug should be gradually withdrawn. Rapid acetylators often respond inadequately even to doses of 100 mg daily and therefore the dose may be raised with only a slightly increased risk of an SLE-like syndrome.

During long-term treatment with Hydralazine, it is advisable to determine the antinuclear factors and conduct urine analysis at intervals of approximately 6 months. Microhaematuria and /or proteinuria, in particular along with positive ANF titres, may be initial signs of immune-complex glomerulonephritis associated with the SLE-like syndrome. If overt clinical signs or symptoms develop, Hydralazine should be withdrawn immediately.

Skin rash, febrile reactions and change in blood count occur rarely and the drug should be withdrawn. Peripheral neuritis in the form of paraesthesia has been reported and may respond to pyridoxine administration or withdrawal of the drug.

In high (cyto-) toxic concentrations, hydralazine induces gene mutations in single cell organisms and in mammalian cells in vitro. No unequivocally mutagenic effects have been detected in vivo in a great number of test systems.

Hydralazine in lifetime carcinogenicity studies, caused, towards the end of the experiments, small but statistically significant increases in lung tumours in mice and in hepatic and testicular tumours in rats. These tumours also occur spontaneously with fairly high frequency in aged rodents.

With due consideration of these animals and in-vitro toxicological findings, hydralazine in therapeutic doses does not appear to bear risk that would necessitate a limitation of its administration. Many years of clinical experience have not suggested that human cancer is associated with hydralazine use.

Precautions

Hydralazine dose or interval between doses should be adjusted according to clinical response in patients with hepatic dysfunction or renal impairment (creatinine clearance < 30 ml/ min or serum creatinine > 2.5 mg/ 100 ml) in order to avoid accumulation of the drug.

Hydralazine should be used with caution in patients with coronary artery disease (since it may increase angina) or cerebrovascular disease.

Patients on Hydralazine who undergo surgery, may show a fall in blood pressure. Adrenaline should not be used to correct the hypotension since it enhances the cardiac-accelerating effects of hydralazine.

Treatment with hydralazine may induce systemic vasculitis. There have also been a small number of reported cases of suspected antineutrophil cytoplasmic antibody ANCA(+) vasculitis in some patients also receiving hydralazine, leading to pulmonary renal syndrome which is a combination of diffuse alveolar haemorrhage and rapidly progressive glomerulonephritis. Patients may present with severe respiratory and/or renal failure and require early diagnosis, discontinuation of the medicine and prompt hospital treatment. The syndrome is characterised by a fulminant course if left untreated, and may sometimes be fatal.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

The following drugs enhance the hypotensive effects of hydralazine:

- Other antihypertensives (diuretics, ACE inhibitors, calcium channel blockers, vasodilators*)

- Anaesthetics

- Tricyclic antidepressants

- Major tranquillisers

- Nitrates or drugs exerting central depressant actions (including alcohol)

*Administration of Hydralazine within an hour or two of diazoxide may give rise to marked hypotension.

The following drugs antagonise the effects of hydralazine:

- Non-steroidal anti-inflammatory agents (especially indometacin)

- Corticosteroids

- Carbenoxolone

- Oestrogens and combined oral contraceptives

Concurrent administration of hydralazine and beta-blockers which are subject to significant first-pass metabolism (e.g. propranolol) may result in increased bioavailability of the beta-blocker. Dosage reduction of the beta-blocker may be necessary in such cases.

MAOI's should be used with caution in patients receiving hydralazine.

Concurrent intake of food has been found to decrease the bioavailability of hydralazine and also to reduce vasodilator effect.

Women of child-bearing potential

Women planning to become pregnant should not take Hydralazine. When pregnancy is confirmed in women taking Hydralazine, the treatment should be discontinued immediately (see subsection Pregnancy).

Pregnancy

Hydralazine readily crosses the placenta with serum concentrations in the foetus being equal to or greater than those in the mother. Animal studies have shown reproductive toxicity (see section 5.3). No serious adverse effects in human pregnancy have been reported with hydralazine use during the third trimester. Thrombocytopenia, leucopenia, petechial bleeding and haematomas have been reported in new-borns whose mother took hydralazine, though these symptoms resolved spontaneously in one to three weeks. Hydralazine should be avoided during the first and second trimesters of pregnancy but may be used later in pregnancy if the mother or foetus is at risk (e.g. pre-eclampsia, eclampsia) or if no safer alternative is available.

Breast-feeding

Hydralazine passes into breast milk but reports to date have not indicated adverse effects on the infant. Breast-fed infants of mothers taking hydralazine should be observed for possible adverse effects.

Hydralazine may cause headache, dizziness and difficulty in concentration, especially at the start of treatment, which can impair the patient's reactions. Hypotension may occur with Hydralazine; it is therefore advisable to exercise caution when driving or operating machinery.

If symptoms are severe, the patient should not drive or operate machinery.

Some side effects of hydralazine such as palpitations, tachycardia, angina symptoms, flushing, headaches, dizziness, gastrointestinal disturbances and nasal congestion are commonly seen at the start of therapy especially if the dose is raised quickly but generally subside as treatment continues.

Adverse reactions are categorised by frequencies as follows: very common (≥ 1/10), common (≥ 1/100 to <1/10), rare (≥ 1/10,000 to <1/1,000) and very rare (<1/10,000).

Blood and lymphatic system disorders:

Rare: leucopenia, neutropenia, thrombocytopenia with or without purpura, anaemia

Very rare: haemolytic anaemia, lymphadenopathy, leucocytosis, pancytopenia, splenomegaly and agranulocytosis

Immune system disorders:

Rare: hypersensitivity reactions such as urticaria, pruritus, vasculitis including pulmonary renal syndrome, eosinophilia, hepatitis

Psychiatric disorders:

Rare: anorexia, agitation, anxiety

Very rare: depression, hallucinations

Nervous system disorders:

Very common: headache

Common: dizziness

Very rare: peripheral neuritis, polyneuritis and paraesthesia (which may be reversed by administering pyridoxine)

Cardiac disorders:

Very common: palpitations and tachycardia

Common: angina symptoms

Rare: heart failure

Very rare: paradoxical pressor responses

Vascular disorders:

Common: hypotension, flushing

Respiratory, thoracic and mediastinal disorders:

Common: nasal congestion

Rare: dyspnoea and pleural pain

Eye disorders:

Rare: increased lacrimation, conjunctivitis

Very rare: exophthalmos

Gastrointestinal disorders:

Common: gastrointestinal disturbances, diarrhoea, nausea and vomiting

Very rare: paralytic ileus

Hepatobiliary disorders:

Rare: jaundice, hepatomegaly, abnormal liver function sometimes in association with hepatitis

Skin and subcutaneous tissue disorders:

Rare: skin rash

Musculoskeletal and connective tissue disorders:

Common: arthralgia, myalgia, joint swelling, SLE-like syndrome (sometimes resulting in a fatal outcome, see section 4.4)

Renal and urinary disorders:

Rare: proteinuria, haematuria sometimes associated with glomerulonephritis

Very rare: acute renal failure and urinary retention

General disorders and administration site conditions:

Rare: fever, weight loss, malaise, oedema

Investigations:

Rare: increased plasma creatinine

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Symptoms

The signs and symptoms of hydralazine overdose include hypotension, tachycardia, headache and generalised skin flushing. Complications can include myocardial ischemia and subsequent myocardial infarction, cardiac arrhythmias, profound shock and coma.

Management

There is no specific antidote. Gastric lavage should be instituted as soon as possible, taking adequate precautions against aspiration and for protection of the airway. An activated charcoal slurry may be instilled if conditions permit. These procedures may have to be omitted or carried out after cardiovascular status has been stabilised since they might precipitate cardiac arrhythmias or increase the depth of shock.

Support of the cardiovascular system is of primary importance. Shock should be treated with plasma expanders if possible, rather than vasopressors. Supportive measures including intravenous fluids are also indicated. If hypotension is present, an attempt should be made to raise the blood pressure without increasing the tachycardia. Adrenaline should therefore be avoided. If a vasopressor is used, one should be chosen that is least likely to precipitate or aggravate cardiac arrhythmia. Tachycardia responds to beta-blockers. Digitalisation may be necessary. Fluid and electrolyte status and renal function should be monitored.

Pharmacotherapeutic group: Arteriolar smooth muscle, agents acting on; hydrazinophthalazine derivatives, ATC Code: C02DB02

Mechanism of action

Hydralazine is a direct acting vasodilator which exerts its effects primarily on the arterioles, with little effect on veins. Its exact mechanism of action is unknown. Administration of hydralazine decreases peripheral resistance and arterial blood pressure, producing a reflex increase in heart rate and cardiac output. These reflex effects can be reduced by concomitant administration of a beta-blocker, thus enhancing the antihypertensive effect. Increased plasma renin activity and sodium and water retention, producing oedema and reduced urinary volume, may also occur with hydralazine administration attenuating its antihypertensive action. These effects can be prevented by concomitant administration of a diuretic.

Absorption

Hydralazine is rapidly and completely absorbed from the gastrointestinal tractafter oral administration but is subject to a dose-dependent first-pass effect. Systemic bioavailability ranges from 26-55% and is dependent on individual acetylator status. The maximum serum concentration of hydralazine after single oral administration of 50 mg Hydralazine was found to be 229 ± 20 ng/mL and 148 ± 15 ng/mL in slow and fast acetylators, respectively. Food may enhance the bioavailability of hydralazine by reducing first-pass metabolism in the gut wall. Peak plasma concentrations are reached after 0.5 – 1.5 hours.

Hydralazine exhibits non-linear pharmacokinetics and it is attributed to the saturable first pass effects.

Distribution

Hydralazine is primarily present as hydrazone conjugate with pyruvic acid in plasma. Hydralazine becomes bound to plasma proteins (chiefly albumin) to the extent of 88-90%. The volume of distribution of hydralazine was determined as 1.5 ± 1.0 L/kg. Hydralazine is rapidly distributed in the body and displays a particular affinity for the blood vessel walls. It is highly protein bound (≈ 90%) in the plasma. Hydralazine crosses the placental barrier and also passes into the breast milk.

Biotransformation

After oral administration the pattern of metabolites depends mainly on the subject's acetylator status.

Systemic metabolism in the liver is by hydroxylation of the ring system and conjugation with glucuronic acid and acetylator status does not affect elimination. The major metabolites are the acetylation product (3-methyl-1,2,4-triazolo-(3,4a)phthalazine) hydralazine piruvic acid hydrazone, which is the major plasma metabolite; and NAc-HPZ (4-(2-aetylhydrazino) phtalazin-1-one, N-AcHPZ (4-(2-aetylhydrazino) which is mostly found in the urine and was found to be the relevant indicator for the drug-related phenotype.

EliminationHydralazine appears in the plasma chiefly in the form of a readily hydrolysable conjugate with pyruvic acid. Its plasma half-life averages 2-3 hours, but is prolonged up to 16 hours in severe renal failure (creatinine clearance < 20 ml/ min) and shortened to approximately 45 minutes in rapid acetylators.

Hydralazine and its metabolites are rapidly excreted by the kidney. Within 24 hours after an oral dose, the quantity recovered in the urine averages 80% of the dose. The bulk of the dose excreted as acetylated and hydroxylated metabolites, some of which are conjugated with glucuronic acid; 2-14% is excreted as “ apparent” hydralazine. Advancing age does not affect either the blood concentration or the systemic clearance of “ apparent” hydralazine. Renal elimination may however be affected insofar as kidney function diminishes with age.

Studies in animals found hydralazine to be teratogenic in mice at oral doses ranging from 20 – 120 mg/kg (20-30 times the maximum human daily dose). Teratogenic effects included cleft palate and malformations of facial and cranial bones. Hydralazine was not found to be teratogenic in rats or rabbits.

In high (cyto-) toxic concentrations, hydralazine induces gene mutations in single cell organisms and in mammalian cells in vitro. No unequivocally mutagenic effects have been detected in-vivo in a great number of test systems.

In lifetime carcinogenicity studies, hydralazine, towards the end of the experiments, caused small but statistically significant increase in lung tumours in mice and hepatic and testicular tumours in rats. These tumours also occur spontaneously with fairly high frequency in aged rodents.

With due consideration of these toxicological findings, hydralazine in therapeutic doses does not appear to bear a risk that would necessitate a limitation of its administration.

Years of clinical experience have not suggested that the use of hydralazine is associated with any risk of cancer in humans.

Tablet core

Cellulose, microcrystalline

Maize starch, pregelatinised

Silica, colloidal anhydrous

Disodium edetate

Talc

Magnesium stearate

Tablet coat

Hypromellose

Diethyl phthalate

Titanium dioxide (E171)

Quinoline yellow (E104)

Hydroxypropylcellulose

Ethylcellulose

Iron oxide red (E172)

Carnauba wax.

Not applicable

3 years

Do not store above 25° C. Store in the original package in order to protect from light.

Polypropylene containers sealed by white polyethylene caps with optional polyethylene ullage fillers or amber glass bottles with wadless plastic caps or PVC/Aluminium blister packs. Each pack type is available in pack sizes of 5, 7, 10, 14, 15, 20, 21, 25, 28, 30, 50, 56, 60, 84, 90, 100, 112, 120, 168, 180, 250 and 500 tablets.

Not all pack sizes may be marketed.

No special requirements.